Designing a mHealth Clinical Decision Support System for Parkinson’s Disease: A Theoretically Grounded User Needs Approach by Timotijevic, Lada et al.
1 
 
 
 
 
Designing a mHealth Clinical Decision Support System for Parkinson’s Disease: 
A Theoretically Grounded User Needs Approach 
 
Authors: 
Timotijevic, La; Hodgkins, C Ea; Banks, Aa; Rusconi, Pa; Egan, Ba; Peacock, Ma; Seiss, Eb; 
Touray, M.M.L.a; Gage, H.a; Pellicano, Cc; Spalletta, Gc; Assogna, Fc; Giglio, Md; Marcante, Ad;  
Gentile, Gd; Cikajlo Ie; Gatsios, Df; Konitsiotis, Sg; Fotiadis, Df 
a University of Surrey, Faculty of Health and Medical Sciences, Guildford, UK  
b University of Bournemouth, Department of Psychology, Bournemouth, UK  
c Fondanzione Santa Lucia, Department of Neurorehabilitation, Rome, Italy 
d Fondanzione Ospedale San Camillo (I.R.C.C.S.), Parkinson’s Department Institute of 
Neurology, Venice, Italy 
e University Rehabilitation Institute, Republic of Slovenia, Soča, Slovenia 
f University of Ioannina, Department of Material Sciences and Engineering, Ioannina, Greece 
g University of Ioannina, Department of Neurology, School of Medicine, Ioannina, Greece  
 
Corresponding author: 
Dr Lada Timotijevic, l.timotijevic@surrey.ac.uk 
 
Contributions 
LT has an overall responsibility for the study delivery. LT, CEH, AB, PR, BE, MP, ES, MMLT 
and HG have conceived the study and developed the protocol. CEH, AB, PR, CP, GS, FA, MG, 
AM, GG, IC, DF, SK and DG collected and analysed the data. LT, CEH, AB, PR, BE, MP and ES 
wrote up the article. All authors reviewed the article. 
 
  
2 
 
 
 
 
Abstract 
Background: Despite the established evidence and theoretical advances explaining human 
judgments under uncertainty, developments of mobile health (mHealth) Clinical Decision 
Support Systems (CDSS) have not explicitly applied the psychology of decision making to the 
study of user needs. We report on a user needs approach to develop a prototype of a 
mHealth CDSS for Parkinson’s Disease (PD), which is theoretically grounded in the 
psychological literature about expert decision making and judgement under uncertainty.  
 
Methods: A suite of user needs studies was conducted in 4 European countries (Greece, 
Italy, Slovenia, the UK) prior to the development of PD_Manager, a mHealth-based CDSS 
designed for Parkinson’s Disease, using wireless technology.  Study 1 undertook Hierarchical 
Task Analysis (HTA) including elicitation of user needs, cognitive demands and perceived 
risks/benefits (ethical considerations) associated with the proposed CDSS, through 
structured interviews of prescribing clinicians (N=47). Study 2 carried out computational 
modelling of prescribing clinicians’ (N=12) decision strategies based on social judgment 
theory. Study 3 was a vignette study of prescribing clinicians’ (N=18) willingness to change 
treatment based on either self-reported symptoms data, devices-generated symptoms data 
or combinations of both.  
 
Results: Study 1 indicated that system development should move away from the traditional 
silos of ‘motor’ and ‘non-motor’ symptom evaluations and suggest that presenting data on 
symptoms according to goal-based domains would be the most beneficial approach, the 
most important being patients’ overall Quality of Life (QoL). The computational modelling in 
Study 2 extrapolated different factor combinations when making judgements about 
different questions. Study 3 indicated that the clinicians were equally likely to change the 
care plan based on information about the change in the patient’s condition from the 
patient’s self-report and the wearable devices. 
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Conclusions: Based on our approach, we could formulate the following principles of 
mHealth design: 1) enabling shared decision making between the clinician, patient and the 
carer; 2) flexibility that accounts for diagnostic and treatment variation among clinicians; 3) 
monitoring of information integration from multiple sources. Our approach highlighted the 
central importance of the patient-clinician relationship in clinical decision making and the 
relevance of theoretical as opposed to algorithm (technology)-based modelling of human 
judgment. 
 
Key words: mHealth; m-health; digital health; Clinical Decision Support System; CDSS; user 
needs; Parkinson’s; mobile devices; wearables 
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1. Background 
We are currently witnessing a paradigm shift in the global provision of healthcare, as new 
technologies are emerging to address growing challenges of cost, quality and continuity of 
healthcare provision. Rapid technological developments such as mobile health technologies 
(mHealth) and data analytics, offer solutions to the current unsustainable healthcare 
systems. “Mobile health” (mHealth), is defined as “medical and public health practice 
supported by mobile devices, such as mobile phones, patient monitoring devices, personal 
digital assistants and other wireless devices” [1].  mHealth is incorporated within the 
broader health informatics framework, though has emerged as a distinctive system in terms 
of context of use and acceptance. The pervasiveness, portability, convenience, immediacy 
and ubiquity of mobile devises  enables not only continuous monitoring and communication 
required for the management of chronic conditions by healthcare providers at lower costs, 
but also patient empowerment to self-manage chronic conditions. Furthermore, the unique 
feature of mHealth is its ability to collect and connect medical, health-related and non-
medical (e.g., behavioural) information that can feed into the existing health informatics 
systems such as electronic medical records and hospital information systems. This 
potentially innovative aspect of mHealth solutions, however, is currently largely confined to 
the non-healthcare context (e.g. lifestyle and public health applications) and lacking in 
acceptable frameworks for its wider adoption into the healthcare systems [2,3] . Diffusion 
of new technologies necessitates clarifying the actual purpose of the innovations both from 
the point of view of healthcare system and the immediate needs of the users of the system, 
including patients and clinicians.  
The need for mHealth-based Clinical Decision-Support System 
For a health informatics system to be useful it needs to address all the complex cognitive 
needs of a clinician’s task. Medical decision making, especially concerning chronic 
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conditions, is characterised by considerable complexity as it is often based on uncertain and 
incomplete information and therefore relies on the clinician’s expertise. The diversity of 
patient presentation and complexity of symptoms, time constraints, characteristics of 
patient–clinician encounter, and limitations of diagnostic tests all increase uncertainty in 
medical decision making, resulting in poor patient outcomes and increased costs [4, 5, 6,7, 
8, 9, 10, 11]. Diagnostic uncertainty is ostensibly a subjective phenomenon based on the 
perceived lack of reliable information for treatment decisions [5]. 
The advances in mHealth such as data analytics and algorithm development based on 
continuous capture of a wide range of structured and unstructured patient-related data, 
can be harnessed to address such uncertainties through a Clinical Decision-Support System 
(CDSS) [12,13], a software that can aid  clinical decision making through careful matching of 
the patient individual factors (e.g., age, sex, ethnicity, computer literacy), their behaviour 
(in-situ and self-reported behaviour) and their current health status, with a computerised 
clinical knowledge base in order to provide patient-specific assessment and 
recommendations about clinical diagnosis/management [14]. A mHealth-based CDSS offers 
the potential to reduce medical errors [15] and improve the quality and efficiency of 
healthcare [16]. Nevertheless, actual application of such systems to date has been limited 
[17]. Several systematic reviews have examined the ability of mobile technology-based 
interventions designed to improve healthcare service delivery [18, 19]. Free et al [18] 
identified a small improvement in outcomes relevant to clinical diagnosis, though the 
potential errors in reports and time taken to process data do caution against a wholesale 
and uncritical adoption of mHealth solutions. Bright et al [20] similarly suggested that the 
evidence of their impact on clinical and economic effectiveness, user satisfaction and 
usefulness is ambiguous, with a range of studies variously demonstrating high, low and no 
difference in satisfaction and usefulness after introducing such CDSS’s in clinical decision 
making. The authors conclude that understanding the ways in which CDSS can meaningfully 
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enhance specific clinical roles is a necessary next step towards the successful 
implementation of mHealth-based CDSS. In developing a mHealth CDSS, therefore, user-
centred design is essential.  
In software engineering, user-centred design comprises several key aspects: a) analysis of 
users’ characteristics and work environments; b) top level functional analysis of users’ goals, 
the domain structures needed for successful goal completion, and information flows within 
a system; c) tasks analysis; and d) representational analysis of user interface [21]. These 
software engineering-driven analytical strategies are mostly performed through ‘use cases’ - 
the industry standard for establishing system requirements. Whilst a use case approach 
facilitates requirement- gathering and subsequent description of the functional 
requirements of a system from a goal-based user perspective [22], it centres on the system 
architecture and system/service quality rather than the system user, is iterative and 
incremental, and mainly driven by the already established system prototype. By contrast, a 
fully user-centred approach precedes the development of the prototype and provides a 
nuanced understanding of intended users’ needs before the process of software 
development even commences.  
In this paper, we report on research of user needs to inform and provide first principles for 
the development of the prototype of a mHealth CDSS [23] for a complex neurodegenerative 
condition – Parkinson’s Disease (PD).  Focusing on this particular chronic condition, our aim 
is to present a novel approach to establishing user needs, utilising a suite of methodologies 
that can be applied to a range of disorders. These methodologies are theoretically grounded 
in the psychological literature about expert decision making and judgement under 
uncertainty. Thus, they address the gap in the currently reported user studies for the 
development of CDSS which often lack a theoretical basis for their study design [e.g. 24]. 
The unique characteristics of PD provide a fertile ground for the implementation of a CDSS 
based on mHealth, but due to its complexity, also present many challenges. 
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Parkinson’s was chosen because of its high prevalence in older adults and its complex and 
ever fluctuating symptom range. PD is the second most common neurodegenerative 
disorder in Europe with more than one million people living with the disease in Europe 
today and this number is forecast to double by 2030 [25]. The economic impact of the 
disease is substantial – the annual European cost is estimated at €13.9 billion [26]. 
Parkinson’s is a complicated disorder that most patients live with for many years and 
decades, becoming increasingly reliant on others to care for them in all aspects of life. The 
highly idiosyncratic presentation of the disease, its unpredictable progression, the plethora 
of possible symptoms both motor (tremor, bradykinesia, rigidity as well as gait/postural 
balance, speech disorders, swallowing disorders) and non-motor (cognitive 
disorders/dementia, depression and anxiety, Impulse Control Disorders, sleep disorders), as 
well as their daily and hourly fluctuation (e.g. motor on-off fluctuations, including freezing 
and dyskinesia’s, and non-motor fluctuations) render the disease particularly difficult to 
manage. The treatment is typically pharmacological, supplemented by occasional 
rehabilitative therapies, and in some cases, surgery.  Clinical decisions are usually based on 
routine patient-clinician meetings (every 3-6 months). In that context, clinician reliance on 
patient and carers’ self-reports may be problematic. The presenting state of the patient may 
not indicate the extent and nature of functional impairments that are experienced at other 
points in time meaning that the clinician cannot gain a full and accurate picture of the 
patient’s status and the disease fluctuations that are crucial for appropriate titration of 
pharmacological treatment. Thus, a CDSS delivering a continuous stream of information via 
a mHealth solution has many obvious attractions, due to its pervasiveness, portability, 
context-sensitivity, immediacy and convenience [27]  
User-centred development of CDSS based on mHealth 
A mHealth-based CDSS promises to deliver objective data about the patient’s healthcare 
status to the clinician in a timely manner [1] but, at the same time, risks increasing 
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"technical uncertainty” [4], that is, the uncertainty due to the increased amount of available 
information, but not necessarily its utility, in making medical decisions. In addition, it has 
been shown that human beings tend to rely more on human judgement rather than on 
evidence-based algorithms, despite the latter being better predictors in many contexts (a 
phenomenon called “algorithm aversion” [e.g. 28]).  
An effective CDSS must be able to collect and link numerous types of patient-related data, 
be they physiological, pharmacological, behavioural and/or psychological measures. When 
developing the CDSS, a decision must be made about what types of data will be collected, 
connected and ultimately delivered to the clinician to optimise their judgment. Optimizing 
medication is the key for the management of PD and to support such functionality, the CDSS 
must employ algorithms that transform the stream of patient data into recognised 
symptoms (in order to recognise a patient’s state), and then to proposed decisions about 
the treatment plan. To develop accurate decision support systems, merely providing patient 
data is not enough; it needs to identify underlying expert models of decision making and 
compare the data against these expert models and clinical guidelines [29].  
This includes an understanding of how clinicians interpret and respond to uncertain 
evidence. The latter is particularly relevant to PD given its multifaceted, complex and 
fluctuating nature [30, 31, 32, 33]. It is important to understand whether and to what 
extent clinicians perceive a certain piece of evidence as informative and whether it is 
coming from a subjective information source (e.g., patient self-reports, diaries, 
questionnaires) or from an objective source e.g., wearable digital health technology, 
neuropsychological assessments, medical assessment techniques (such as Magnetic 
Resonance Imaging (MRI), blood samples). [34, 35, 36]. 
Early user (clinician) engagement with the design process and well-structured studies of 
user needs and their cognitive demands are therefore a necessary component of mHealth-
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based CDSS design and essential to increasing the usefulness, efficacy and acceptability of 
mHealth technologies. However, user engagement in the development of the CDSS is poorly 
reported and often given only a cursory role in the design. There is limited evidence of 
extensive exploration of clinicians’ decision-making processes, and how interventions will fit 
into routine clinical workflow. Previous design projects on CDSS for Parkinson’s, PERFORM 
[37], REMPARK [38] and SENSE-PARK [39], surveyed the factors influencing clinicians’ 
pharmacological decision-making – for instance, Serrano et al [24] report on the 
participatory design process to achieve a consensus among patients, clinicians and 
technologists over the selection of a set of symptom domains to be continuously assessed. 
The reviewed projects, however, mainly focused on information needs and none examined 
in-depth the clinicians’ expert judgement models that are active in situ – the contexts 
characterised by the specific presentation of symptoms. Importantly, none of these 
approaches were grounded in the theoretical literature around task analysis, cognitive 
demands, expert judgments and cognitive processes under the conditions of the varying 
degrees of certainty. This limitation was addressed in the studies reported below. 
Aims and overall approach 
We report on PD_Manager, a case study of clinicians’ user needs for the development of a 
mHealth-based CDSS designed to help clinicians to monitor motor and non-motor 
symptoms using easily portable devices such as smart phones, wristbands and sensor 
insoles, worn by patients, to capture objective data about their fluctuating condition. The 
system is intended to combine machine learning and decision support methods with mobile 
and cloud-based approaches and share data via the cloud enabling clinicians to follow 
patients’ status closely. In this way, the PD_Manager CDSS enables continuous and accurate 
patient monitoring and PD symptoms assessment, delivered in a timely manner (see Figure 
1).  
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Figure 1. Implementation of the CDSS for the clinician 
 
The aim of the mHealth-based CDSS is to enable the monitoring of patients, fluctuation of a 
range of symptoms or medication/treatment adherence, so that management plans can be 
evaluated and indications for modifications to medication regimens identified. The models 
for PD_Manager CDSS were developed through a combination of data mining of various PD 
symptoms; expert modelling using a qualitative multi-criteria method DEX, and assessment 
of models in terms of classification accuracy, transparency, correctness and completeness. 
This methodology is reported in a separate publication [40]).  
Due to the nature of the decision making (i.e. medication changes in a progressive chronic 
disease), which rarely if ever regards life threatening or emergency events, Quality of 
Services (QoS) aspects such as latency, priority and bandwidth were not critical for the 
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development of the CDSS. Data loss was minimized as much as possible given that the 
system adopted commercial sensors. Other QoS aspects, such as power consumption were 
very important for the patient experience with the system and were taken into 
consideration both for the design of the system and for the pilot implementation. Data 
security was also addressed in the design and implementation of the mHealth system and 
was the main requirement for QoS within the PD_manager context. 
In order to develop an initial set of principles for the CDSS, a series of user-needs studies 
were initially conducted, which we are reporting in this paper. The overall objective of our 
user-centred approach was to identify: 
I. What types of decisions clinicians make when managing a patient with PD? 
II. Information needs of the clinicians: What factors and their combination related to the 
patient symptoms inform their decisions? 
III. Judgement under conditions of varying degree of certainty: The perceived value of self-
reported patient data vs mHealth-generated data for a range of clinical decisions.  
The following suite of three studies were conducted: 
Study 1 - Hierarchical Task Analysis (HTA) including elicitation of user needs, cognitive 
demands and perceived risks/benefits (ethical considerations) associated with the proposed 
CDSS.  
Study 2 - Computational Modelling of Clinicians’ Decision Strategies. 
Study 3 - Vignette-based study of the relative value of self-reported vs CDSS-generated 
evidence for clinicians’ decision making. 
Study 1 utilised Hierarchical Task Analysis (HTA) through structured qualitative interviews, 
[41] as the framework for examining tasks associated with the clinical management of PD in 
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terms of goals and sub-goals as well as the ethical considerations likely to arise when 
clinicians use mHealth-based CDSS. HTA, a core ergonomics methodology, is the established 
precursor for exploration of cognitive demands associated with human performance across 
a wide variety of domains and applications. 
Study 2 is grounded in social judgement theory and related methodology [42]. This method 
has been used in many areas, and there has been extensive research on clinical judgement 
using it in a number of medical domains including studies of chronic heart failure [43], the 
management of rheumatoid arthritis [44], and decisions to use dialysis [45]. This approach 
aims to describe judgments through the combination of cues, such as signs or symptoms 
that are used to diagnose a cause or predict an outcome. Previous research on Parkinson’s 
disease has identified a comprehensive set of symptoms of relevance to managing the 
disease [46, 24]. Whilst this objective set of symptoms provides a useful framework of 
possibilities, which of these symptoms users actually use in their judgement process is a 
different question. A common finding across all domains of professional judgments, 
including medical judgments, is that the cues people actually use in their decisions are not 
the same as the cues they explicitly report using [47]. Experts use less information when 
making decisions than novices [48] and often disagree about their judgments [49]. Fully 
understanding user needs therefore requires an approach that captures the variation, 
context, and subjective weighting of each piece of information for individual users. 
Study 3 builds on this recognition of the need to contextualise experts’ medical decision 
making by further exploring the situated nature of these judgements. It recognises the 
importance of understanding whether and to what extent clinicians perceive a certain piece 
of evidence as informative as a function of whether it comes from a subjective (e.g., 
patients’ self-reports, diaries) or from an objective (e.g., wearable technology, 
electrophysiological and neuroimaging techniques) source [35, 36]. In addition, we explore 
the uncertainty inherent in evaluating these types of evidence in situ by varying the degree 
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to which the evidence from the two sources are congruent with each other. We deploy 
vignettes, a methodology that has already been successfully used to study how novices and 
experts make judgements in conditions of uncertainty based on patients’ self-reports as 
well as objective evidence, such as a physical symptom [50, 51, 52].  
The data were collected between 2015 and 2017. Since the three studies collected data 
from clinicians (not patients), a formal ethical approval was not required within any of the 
national legislations (UK, Greece, Slovenia and Italy). However, within the UK, Research & 
Development approval from the hospital trusts - the two hospitals that allowed access to 
the clinicians - was obtained. For each study, written Informed Consent was obtained from 
the participants. 
2. Method 
Study 1: Hierarchical Task Analysis  
Data were collected across four culturally diverse sites (UK, Italy, Slovenia and Greece) and 
from two core user groups: Prescribing Clinicians (consultant neurologists, hospital doctors, 
GPs and Parkinson’s Disease Nurse Specialists (PDNS) and Supporting Clinicians 
(physiotherapists, occupational therapists, psychologists, speech therapists). A mixed-
method approach was used whereby Prescribing Clinicians were interviewed one-to-one 
and Supporting Clinicians were either interviewed one-to-one or took part in a small focus 
group. The Prescribing and Supporting Clinicians recruited for the study are detailed by 
country (Table 1). 
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Table 1. Participant description 
 UK  
n=6 
 
 n 
 
Italy 
n=15 
Greece 
n=8 
Slovenia 
n=18 
Total 
N=47 
Prescribing Clinicians      
Consultant neurologist 2 4 8 7 21 
Parkinson’s Disease Nurse Specialist  3 - - - 3 
General Practitioner  1 5 - 3 9 
Supporting Clinicians      
Physiotherapist - 2 - 2 4 
Occupational therapist - 1 - 2 3 
Psychologist - 3 - 2 5 
Speech therapist - - - 2 2 
 
The added value of our cross-cultural approach is the ability to account for diverse models 
of clinical work organisation. Whilst working in multi-disciplinary teams for complex 
neurological diseases such as PD is standard practice in state medical systems such as UK, 
Italy and Slovenia, the Greek system is characterised by a predominant role of consultant 
neurologists within the state system, supplemented by specialist treatment in the private 
system.  
The first step was to clearly define the overall task under analysis and the specific purpose 
for that analysis. Within this study the top-level task and goal were collectively defined as:  
‘Effective management of Parkinson’s Disease in order to identify where the 
proposed outputs of the PD_manager project can add value to the task’. 
There followed a desk-based review of current practice from the literature resulting in the 
development of a preliminary Hierarchical Task Diagram (HTD). Utilising this preliminary 
HTD as a stimulus, data were collected from the prescribing and supporting clinicians via 
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structured qualitative interviews (locally, within each of the 4 countries) to expand our 
understanding of the task, to determine task sub-goals and ultimately to achieve full task 
decomposition. During the interviews clinicians were asked to reflect on the preliminary 
HTD and suggest any changes/amendments to accurately reflect the broadest range of tasks 
they typically undertake. Cognitive demands, decision-making strategies, perceived 
usefulness of symptomatic data, perceived importance of patient adherence, supporting 
therapies and beliefs about mHealth-based CDSS (including ethical considerations) were 
elicited in parallel by a generalist approach within the interview to allow us to encompass 
the whole domain more effectively.   
Study 2: Modelling Clinicians’ Decision Strategies 
The aim of this study was to develop a model of how clinicians use information from 
patients with Parkinson’s Disease in the management of Parkinson’s disease using a 
factorial survey design. We elicited the decision-making strategies of clinicians, describing 
how strongly weighted each of the factors are within their overall judgements. Prescribing 
clinicians assessed twenty-four cases, each one describing the symptoms of a different 
patient. For each case, clinicians were asked to make judgements about the patient. 
Specifically, they made judgements about changing the care plan, change to Levodopa, and 
change to dopamine agonist. In each case, thirteen key symptoms or factors in the 
assessment of Parkinson’s disease were varied systematically. These were: bradykinesia, 
rigidity (stiffness), tremor, gait and balance, sleep, cognitive functioning, depression, 
constipation, motor fluctuations, dyskinesia, impulsivity, age and employment status. The 
changes in these symptoms were described to clinicians in terms of a comparison to a 
consultation three to four months previously. That is, each of the symptoms was described 
as ‘better’, ‘same’, or ‘worse’ than three to four months previously. Two contextual factors 
were: age (either ‘55 years old’ or ‘75 years old’) and employment status (either ‘employed’ 
or ‘retired’). Participants were informed that in all cases they should assume that the 
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patient with Parkinson’s Disease was currently taking Levodopa and a dopamine agonist, 
the disease duration is 5-10 years and their disease severity is stage 3 on the Hoehn and 
Yahr scale [53] (please see the Table 2 for an example of a case).  
Table 2. An example of the Study 2 case 
Demographics Motor Symptoms Non-motor symptoms Treatment adverse 
effects 
75 years old, 
retired 
Bradykinesia Worse Sleep Better Motor 
fluctuations 
Same 
Rigidity 
(stiffness) 
Worse Cognitive 
functioning 
Same Dyskinesia Better 
Tremor Worse Depression Same Impulsivity Better 
Gait & 
balance 
Same Constipation Better   
 
Study 3: Vignette study of value of different types of information for clinicians’ diagnostic 
strategies 
The study aim was to investigate clinicians’ decision making about treatment and care plans 
based on the relative utility of subjective (reported by a patient with Parkinson’s Disease) or 
objective (digital health) information. Prescribing clinicians completed an online 
questionnaire with 15 vignettes describing situations involving hypothetical patients with 
Parkinson’s Disease (the surnames used in the vignettes were not of real patients). For all 
vignettes, the main information about the patients was kept constant: they were described 
as older (between 66 and 70 years old), living with their partner, with their symptom 
17 
 
 
 
 
severity at Hoehn and Yahr stage 3, disease onset was seven years ago, and the current 
therapy as prescribed for the past six months. Furthermore, we randomly varied the 
patients’ gender across the 15 vignettes. 
Two within-participant variables were manipulated in these vignettes: information type (5 
levels) and symptoms/signs (3 levels). We manipulated the type of information presented to 
the clinicians as follows (see Table 3): subjective information (patients’ self-report); 
objective information (digital health data); congruent subjective and objective information 
(both sources suggested a decline in patients’ symptoms/signs); incongruent subjective and 
objective information (one indicating a decline and the other indicating an improvement).  
Table 3. Information about the manipulated information type variable in Study 3 
Variable Levels 
Information 
type 
Subjective 
(self-report) 
Objective 
(device 
outcome) 
Subjective & 
objective –
congruent 
Subjective & 
objective –
incongruent 
Self-report: 
decline 
Devices: 
improvement 
Subjective & 
objective –
incongruent 
Self-report: 
improvement 
Devices: 
decline 
 
For each information type, we devised three different scenarios where the main difference 
was the symptom/sign: (1) bradykinesia [54, 55], and impaired dexterity, (2) gait and 
postural stability, and (3) sleep. The following is a sample vignette presented to participants 
depicting a case of incongruence between the patient’s self-report (indicating a decline in 
gait and postural stability) and a sensor insole (indicating an improvement): 
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“Mr Briggs is 69 years old, retired, and he lives with his wife. He suffered from the 
first symptoms of PD approximately seven years ago (Hoehn and Yahr stage 3).      
In a consultation with you, the patient tells you that he feels that his condition has 
worsened and he has been experiencing more falls and gait difficulties.      
Data from the patient’s sensor insole, a device which has captured information on his 
PD symptoms, show that he has improved and has experienced a decreased number 
of falls and gait difficulties since his last clinical consultation.       
The patient has been receiving medication and physiotherapy treatment over the last 
6 months.” 
After reviewing each vignette, participants were asked to select a decision about the 
therapy (“Based on this information, how likely would you change the patient’s care plan?”) 
using a 7-point Likert scale (1 = very unlikely, 7 = very likely), and about the confidence in 
the decision (“How confident are you in the answer you have just given?”, 1 = not at all 
confident, 7 = very confident). Finally, they were asked to indicate what type of data they 
would find more useful in order to increase confidence in their decision – subjective (PD 
patient’s self-report) or objective (devices-generated) data (“Given your decision, how 
useful would you find it to seek for more information from the patient or the devices to 
increase your confidence?”). They used two 7-point Likert scales (1 = not at all useful, 7 = 
very useful) to provide their answer for both the self-report and the device-generated data. 
After completing the vignettes, participants’ socio-demographic data (including age, gender, 
and nationality) were collected. The survey lasted approximately 30 minutes. 
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3. Results 
Study 1: Hierarchical Task Analysis 
Analysis of the qualitative data comprised a mixture of summative content and thematic 
analysis [56]. Coding structures were developed to guide the analysis of the data and ensure 
a harmonized and standardized approach to analysis of the data across the different 
countries. The resultant data were used to develop an updated version of the Hierarchical 
Task Diagram validated by the interview process (Fig 2).  
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Figure 2. Hierarchical Task Analysis Diagram reflecting sub-goals and task operations for both Prescribing and Supporting Clinicians 
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The majority of clinicians interviewed in this study operated in an environment with little or 
no access to continuous objective data on PD motor symptoms to support their clinical 
decision making, even at its most basic level. Therefore, the provision of this type of data in 
graphical form by the mHealth-based CDSS was deemed to be useful. Having identified the 
cognitive demands and difficulties clinicians experienced when managing patients and their 
expressed needs (Appendix 1) as well as the perceived usefulness of data on the various 
motor and non-motor symptoms (Appendix 2), a set of user-derived requirements for the 
mHealth-based CDSS design were proposed (Appendices 3 and 4).  
Approaching the development of user needs using this methodology, the outcomes of this 
study suggested a move away from the traditional silos of ‘motor’ and ‘non-motor’ 
symptom evaluations and suggest that presenting data on symptoms according to goal-
based domains would be the most beneficial approach. This innovative goal-based domain 
approach including: Diagnosis indicators; Disease progression indicators; Pharmacological 
decision support; Patient Safety; Overall QoL indicators; Physiotherapy/ occupational 
therapy; Psychology and Speech therapy (Appendices 3A -3B) would facilitate the 
collation/integration of the relevant non-motor symptom data with the motor symptom 
data for each of these domains in more targeted and user-friendly interfaces. Furthermore, 
the data suggested that the most useful symptoms to evaluate should be driven by the 
importance the patient themselves attribute in terms of their overall QoL. Therefore, it was 
suggested that design should deliver functionality to allow for the creation of personalised 
user interfaces that provide flexibility for Clinicians/Patients to identify and select which 
symptoms they wished to consider at any one time. The availability of such a flexible system 
should allow clinicians to focus on the data they needed to engage with, to better facilitate 
patient engagement in shared decision making and potentially achieve better adherence 
and clinical outcomes.  
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Finally, the content analysis of attitudes towards the technology and ethical issues indicated 
that the participants were not aware of any ethical issues associated with the mHealth-
based CDSS. There seemed to be a general agreement that the systems needed to manage 
privacy concerns were already in place such as, for instance, data management processes 
and consent forms. However, when asked whether they were aware of any governance 
guidelines /codes of practice regarding the collection and transmission of patient data using 
technology, none of the participants were able to refer to these systems within the context 
of their work. 
Study 2: Modelling Clinicians’ Decision Strategies 
Twelve prescribing clinicians (7 males and 5 females), with a mean age of 45.58 years, (SD = 
8.76) from 4 countries: Italy (n = 3), Greece (n = 2), Slovenia (n = 3) and the UK (n = 4) took 
part in the study. They were consultant neurologists (n = 9), consultant gerontologist (n = 1) 
and general practitioners (n = 2). These clinicians saw a mean of 172.67 patients with 
Parkinson’s Disease per year (SD = 215.26). Multiple regression was used for each clinician 
to determine the weighting of each of the factors on each of the judgements. The 
judgement patterns were calculated for each participant individually based on their 
responses to the judgement task. Each of the factors within the cases was coded as an 
independent variable and the judgements made about each case were the dependent 
variables. The R2 value for the regression model describes how well the factors explain the 
judgements made and the standardised beta weights for each factor describe the weighting 
of that factor in the judgement. Table 4 presents the beta weights for each factor in each 
judgement and the R2 for each model.  
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Table 4. Standardised beta weights for the mean response to identify the factors predicting changes 
to treatment 
Factor Care Plan Levodopa Dopamine Agonist 
Bradykinesia .36 .31 .14 
Tremor .51 .47 .44 
Gait -.02 .16 -.04 
Dyskinesia .19 -.29 .31 
Motor Fluctuations .44 .44 -.16 
Sleep .10 .04 .19 
Cognition .23 .27 .00 
Impulsivity -.09 -.07 -.36 
Depression .22 .08 .27 
Constipation -.02 -.10 .06 
Rigidity .35 .41 .34 
Age -.31 -.07 .00 
Employment -.37 -.29 .26 
Model R2 0.82 0.90 0.70 
N.B. for symptoms, a positive beta weight implies an increased likelihood of change to the 
care plan, or an increased level of medication, in response to worsening symptoms. 
 
Across the different models, findings showed that clinicians were more likely to change the 
care plan and increase the level of medication when presented with worsening symptoms, 
with the exception of a reduction in Levodopa with worsening dyskinesia and a reduction in 
24 
 
 
 
 
dopamine agonist with worsening impulsivity. Analysing the findings in more detail provides 
some more specific results. Across the different judgements, the factors that dominate the 
decision are motor symptoms: bradykinesia; rigidity; motor fluctuations; and tremor. Non-
motor symptoms such as depression, impulsivity and cognitive function explained some 
variance in the judgements, albeit less than bradykinesia, rigidity, motor fluctuations and 
tremor, but sleep and constipation had very little effect on the judgements made. Some 
factors were weighted more similarly by all clinicians, e.g. tremor, whereas others were 
weighted more differently, e.g. bradykinesia. Furthermore, the study shows that different 
factor combinations (e.g. symptom, age, employment status) are important when making 
judgments about different questions (e.g. changing the care plan, change to Levodopa, and 
change to dopamine agonist). 
Study 3: Vignette study of value of different types of information for clinicians’ diagnostic 
strategies 
Participants were N = 18 (10 females; 8 males) prescribing clinicians practicing in Greece (8), 
Italy (5), the UK (4), and Slovenia (1). Their mean age was 41.94 (SDage = 7). They were 
consultant neurologists (13), general practitioners (2), consultant gerontologist (1), 
neurology resident (1), and researcher (1). 
In our analyses, given that our main variable of interest was Information Type, we averaged 
participants’ responses across the three primary symptoms. The results indicated that the 
clinicians were equally likely to change the care plan based on information from the 
patients’ self-report and the devices about the decline of their condition. In addition, they 
were more likely to revise the care plan when they received congruent information from 
both sources and less likely to revise the care plan when they received conflicting 
information from both sources.  
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Figure 3. Mean likelihood of changing the patients with Parkinson’s Disease care plan as a function 
of the different pieces of information presented to participants in the scenarios (i.e., self-report only, 
devices’ outcome only, consistent (congruent) or conflicting (incongruent) information from both 
sources). Error bars represent 95% confidence intervals. 
 
The findings about clinicians’ confidence in their decision mirrored these findings. Clinicians 
were equally confident in changing the care plan when receiving information from only one 
information source, most confident when the information from both sources was congruent 
and least confident when it was incongruent. 
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4. Discussion 
As highlighted by Castro et al [57] a crucial question to ask in the development of a CDSS is: 
What is the system intended for? Therefore, the early understanding of user needs is the 
most important aspect of system development. And yet, the predominance of the software 
engineering-driven CDSS development with a main focus upon information needs of a user 
and use cases based on the already established prototypes [24], is unlikely to provide a full 
account of the social (e.g., the interactions between patients, caregivers, and clinicians; 
time constraints) and psychological (e.g., clinicians’ judgement and decision-making 
strategies) realities within which the technology will be operationalised. We addressed 
these shortcomings in our research.  
Our approach to user studies was developed to identify the core principles of design to 
guide an early development of the CDSS. Based on our findings, we can formulate three 
main principles of design with some important theoretical and practical implications: 1) 
enabling shared decision making between the clinician, patient and the carer; 2) flexibility 
that accounts for diagnostic and treatment variation among clinicians; 3) monitoring of 
information integration from multiple sources.  
Implications for the system design  
Our study highlighted that the primary goal of the system should be to enable shared 
decision making between the clinician (e.g., neurologist, PD nurse, physiotherapist), patient 
and the carer [58, 59]. This is evident in several findings: our HTA interview study (Study 1) 
has highlighted that the needs of clinicians should be conceptualised in terms of how the 
system is likely to support the clinician-patient interaction. The practical implication of this 
finding is that the design should be driven by the patient-specific goal-based domains rather 
than the expert-defined symptom categorisation. Study 1 identified that the most useful 
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symptoms to evaluate should be decided by the importance patients themselves attribute 
to those symptoms in terms of their overall QoL. A mHealth-based CDSS should therefore 
be conceptualised as a vehicle that facilitates co-production of disease management 
solutions and should be embedded within the context of patient-clinician interaction.  
The shared nature of decision making extends the approach to decision making applied in 
Study 2. Previous work applying social judgement theory to clinicians’ decision making uses 
a paradigm in which an individual clinician is presented objective information and forms a 
judgement about the patient. From this analysis their personal evaluation can be inferred 
[43, 44, 45]. The context of this study demonstrates that an individual clinicians’ weighting 
of cues is not the only consideration. Instead, the weighting of symptoms and desirability of 
outcomes may emerge through the interactions of clinicians, patient, and carer. Study 3 
extends the approach to decision making, demonstrating how the weighting of this 
information is also influenced by its source – the patient’s subjective report or digital 
device, thus highlighting again the key role of the clinician-patient interaction and 
communication. The unique context of mHealth devices, in comparison to digital devices in 
more established settings such as hospitals, further influences their interpretation. 
Secondly, our suite of studies highlighted that the system should take into account 
diagnostic variation [5] as well as treatment variation among clinicians. In other words, a 
CDSS should allow different judgement patterns for the disease management to operate for 
similarly presented symptoms. The evidence for this principle emerged from Study 2, which 
identified similarities in the way clinicians evaluate symptoms, which, nevertheless, may be 
linked to significant variations in the way in which the disease is ultimately managed. Whilst 
the study did not report on the actual causal models underpinning this variability, it 
indicated that different users are likely to prefer different information in management of 
the disease. This variation is potentially driven by not only symptoms presentation but also 
the immediate as well as broader context of patients’ lives. Again, this illustrates that it is 
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not possible to define a set of the most important factors for all cases, but rather, that the 
system must have an inbuilt flexibility to allow the operation of different solutions 
representing co-production by clinician and patient, which would improve the completeness 
and usefulness of the model. This flexibility should be combined with a method to optimize 
the quality and overall performance of the decision-making process. The recent 
developments in quality of service-based web- service selection [60] may be one way 
forward in the identification of the most important factors that address user needs and 
increase user satisfaction whilst maintaining system flexibility. 
Finally, our work pointed to the necessity for a system to fully account for and continuously 
monitor the shortcomings, risks and compromises inherent in integrating quantitatively 
different types of information from multiple sources. Study 3 provides evidence that the 
combination of information from the patient and from the mHealth devices can 
differentially influence experts’ decisions and their confidence in those decisions. This is 
demonstrated by the statistically significant differences between the conditions in which 
both types of information were presented (i.e., the congruent and incongruent conditions) 
and the conditions in which only one source of information (either the patients’ self-report 
or the devices’ outcomes) was available. The lack of difference, both in terms of their 
impact on the care plan revision and the confidence levels, between the patients’ self-
reports and devices’ outcomes suggests that clinicians consider the - ostensibly subjective - 
information provided by patients as equally useful and trustworthy as the objective 
information generated by the devices. This finding about the clinicians’ reliance on 
subjective as well as objective evidence is inconsistent with the view that technology-based 
evidence is unbiased, more ecologically valid, and more reliable than subjective assessment 
[32, 33, 61, 62].  It supports our first principle, however, that puts an emphasis on the 
patient-clinician relationship as a focal point of the CDSS. 
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This finding bears on the actual implementation of a mHealth-based CDSS. In particular, it 
would be important to identify conditions, risks and mechanisms that could give rise to 
conflicting information and the impact that this could have on disease management and 
patients’ care. Mechanisms and procedures could then be put in place to deal with these 
situations as well as to prevent circumstances in which clinicians are reluctant to change the 
treatment (as it was the case in the presence of conflicting information from the patients 
and the devices in Study 3). These are situations that can generate technical uncertainty, 
whereby paradoxically the knowledge is inadequate, even if data and technology are 
available [4]. Furthermore, uncertainty could be used to justify risk discounting or inaction 
[63, 64], mHealth based CDSS should therefore not only provide appropriate and reliable 
evidence to aid clinical judgments, but also aim to reduce the uncertainty inherent in 
natural decision-making contexts experienced by clinicians –when a clinician and a patient 
are actually interacting.  
Finally, we would like to comment on one surprising finding indicating that, at the time of 
the interviews, the clinicians appeared to have no ethical concerns associated with the 
advent of data analytics and mHealth into their clinical practice. Ethical judgments of 
clinicians are currently covered by the established principles of medical decision making - 
the Hippocratic Oath of “do no harm” and the Helsinki declaration [65] of having 
appropriate oversight of data management and the need to seek patient consent. However, 
the huge advances in the field of Artificial Intelligence and mHealth must be accompanied 
by rapid education to prepare clinicians for assessing the ethical implications of using these 
systems in their interactions with patients. Of particular concern is the issue of the 
accountability of technology – both in terms of its ability to provide trusted and relevant 
information, but also in terms of its ability to recount and feedback the way in which 
algorithms are providing the data for the mHealth-based CDSS (explainability). This directly 
links to the issue of how the assessments of accountability and responsibility of the clinician 
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can be established in situations where they may not be able to assess the reliability or 
usefulness of information that technology provides, and when they may not be able to 
meaningfully assess the consequences of their judgments. It is the latter issue that calls for 
clinicians’ critical awareness of the nature of such technology and the possible biases that 
may be perpetuated throughout the life cycle of a technological system. Engaging clinicians 
in these discussions is essential in order to prevent the deterioration of patient trust and 
ensure effective healthcare delivery based on any future mHealth CDSS. 
Future research should seek to explore the relevance of the core principles for mHealth-
based CDSS development identified by this study in the Parkinson’s domain in other chronic 
disease domains. We focused on a specific, multifaceted, and fluctuating neurodegenerative 
disease, but it is possible that for each chronic-disease domain these core principles may 
need to be tailored to some degree. However, the utilisation of the theoretical and 
methodological framework described here would facilitate the identification of any domain-
specific issues. 
5.  Conclusions 
Being guided by psychological theory enabled us to move beyond mere information -
gathering to develop core principles for designing a Parkinson’s mHealth based CDSS. We 
developed a novel approach to address the questions of the system’s core purposes, which 
provided a more nuanced accounting of clinician judgment in situ and helped formulate a 
vision for the mHealth-based CDSS system functionalities. This vision highlights the central 
importance of the patient-clinician relationship in clinical decision-making and the relevance 
of theoretical as opposed to algorithm (technology)-based modelling of human judgment. It 
challenges the assumption that augmented decision making - based on the operation of 
algorithms - is the best solution to better clinical decision making, instead establishing 
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human decision making as central in the increasingly machine- and data-driven world of 
healthcare. 
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Summary points 
 There has been limited evidence of the widespread implementation and acceptance 
of mHealth based Clinical Decision Support Systems (CDSS). 
 The needs of the users of mHealth CDSS (i.e. clinicians)  in terms of the cognitive 
demands of clinical decision making under uncertainty are not explicitly explored in 
the of design mHealth-based CDSS. 
 Our research on clinicians’ user needs for the development of Parkinson’s mHealth-
based CDSS is theoretically grounded in the psychological literature about expert 
decision making and judgement under uncertainty. 
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 It highlighted the central importance of the patient-clinician relationship in clinical 
decision-making and the relevance of theoretical as opposed to algorithm 
(technology)-based modelling of human judgment. 
 
 
